The next round of Medicare's historic drug price negotiations could save billions for seniors taking medications like Ozempic ...

Employers have absorbed the majority of cost increases over the past four years, and they likely cannot continue to do so,” ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

CVS Health’s first quarter results reflected steady execution across its core businesses, with management highlighting ...

Novo Nordisk has terminated its partnership with telehealth company Hims & Hers Health, accusing it of deceptively marketing weight-loss drugs.

Curay, the acting director of the FDA’s Center for Drug Evaluation and Research, internally announced her retirement Monday.

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its ...

Wegovy, which has been used for weight loss reasons, is not going to be covered by a Medicare Advantage plan or for Part D if it's prescribed for weight loss reasons.